

OPTIMIZATION OF THE PROCESS EXTRACTION  
AND DRUG RELEASE OF FISH GELATIN  
NANOPARTICLES DERIVED FROM TILAPIA  
(*OREOCHROMIS SPP*)

BY

DENI SUBARA

A thesis submitted in fulfillment of the requirement for the  
degree of Doctor of Philosophy (Engineering)


Kulliyyah of Engineering  
International Islamic University Malaysia

FEBRUARY 2021

## ABSTRACT

Gelatin is one of the popular biopolymers used for food and pharmaceutical applications, given its capability to dissolve in aqueous environments and to form nanoparticles that enable the encapsulation of various active agents into stable products. On the other hand, coupled with these capabilities and recognition by the US Food and Drug Administration (FDA) authority, as Generally Recognized as Safe (GRAS) material, it has attracted growing interest and attention from researchers to produce gelatin nanoparticles toward encapsulating various food and pharmaceutical molecules. However, even though gelatin can be produced from mammalian and fish, it is quite challenging since all sources of gelatin nanoparticles in the market originate from mammalian gelatin, which is either bovine or porcine. Although the use of such gelatin as highlighted by Muslims, Jews, and other religious backgrounds is an issue. Furthermore, there are no publications regarding gelatin nanoparticles from fish gelatin published at this stage, which further adds to this problem. Therefore, this study aims to prepare and characterize fish gelatin nanoparticles (FGNPs) and FGNPs encapsulated with an active agent. Fish gelatin was first extracted from Tilapia fish skin employing a two-step desolvation method in producing FGNPs. The initial first desolvation step was optimized to obtain consistent high molecular weight at the gelatin concentration, temperature, centrifugation speed, and centrifugation time of 9%, 45 °C, 12000 xg, and 5 min, respectively. As an outcome from this work, a new method to produce significant FGNP properties consistently was created based on this step. A second desolvation step adopting the two-step desolvation method was also optimized in which significant factors were screened using Plackett-Burman experimental design, determining that the pH, acetone percentage, and glutaraldehyde volume were the significant factors. These factors were then optimized using factorial design, indicating that FGNPs with a size of  $198.46 \pm 6.1$  nm were produced using pH, acetone concentration, and a glutaraldehyde volume of 2.45, 16%, and 400  $\mu$ l, respectively. Indeed, increasing pH and acetone concentration led to an increase in the size of particles, whereas increasing the volume of glutaraldehyde decreased the size of FGNPs. Accordingly, this work makes a valuable contribution by developing an optimized production process, thereby demonstrating the potential for the future application of FGNPs. This study has also shown that fish gelatin could be used as an alternative for mammalian gelatin for producing nanoparticles. Here, the production process of drug-loaded FGNPs was optimized in which the significant factors were screened using factorial design for encapsulation efficiency. The drug amount was also found to have a significant effect, whereas pH, acetone percentage, and the glutaraldehyde amount with stirring time was not significant concerning the encapsulation efficiency of drug-loaded FGNPs. Notably, increasing the drug amount increased encapsulation of drug-loaded FGNPs in which an encapsulation efficiency of 39%, was observed. The physicochemical characterization of the optimum formulation, as suggested, was also examined using a Scanning electron microscope (SEM), transmission electron microscopy (TEM), and atomic force microscopy (AFM) showing FGNPs having a smooth surface. Fourier-transform infrared diffraction (FTIR) revealed the presence of the drug in tailored FGNPs, and Powder X-ray diffraction (XRD) analysis highlighted the formation of amorphously dispersed systems having a slightly faster release profile of drug-loaded FGNPs with a biphasic

release profile. The release mechanism followed non-fickian diffusion, meaning that the release of the drug from FG NPs was governed by diffusion and erosion of the matrix.



## خلاصة البحث

الجيلاتين هو أحد البوليمرات الحيوية المنتشر استعمالها في الاستخدامات الغذائية والصيدلانية. قدرتها على الذوبان في البيئات المائية وقابليتها لتشكيل الجسيمات النانوية تمكنها من تغليف العوامل النشطة المختلفة في شكل منتجات مستقرة. من ناحية أخرى، إلى جانب هذه القدرات فقد زاد الاعتراف بها من قبل إدارة الغذاء والدواء الأمريكية كمواد آمنة من اهتمام الباحثين في إنتاج جزيئات نانوية للجيلاتين وتغليف الجزيئات الغذائية والصيدلانية. وعلى الرغم من قدرة الثدييات والأسماك على إنتاج الجيلاتين، فإنه من السليبيات كون جميع مصادر الجزيئات النانوية الجيلاتينية في السوق هي جيلاتين الثدييات إما بقرية أو خنزيرية، حيث يعتبر استخدامها أحد المشاكل الرئيسية التي يواجهها المسلمون والمهود وغيرهم من الخلفيات الدينية. علاوة على ذلك فإن المؤلفات العلمية عن الجسيمات النانوية الجيلاتينية من جيلاتين الأسماك غير موجودة حتى الآن. ولذلك فإن الهدف من هذه الدراسة هو إعداد وتوصيف الجزيئات النانوية الجيلاتينية السمكية وتغليف عامل نشط بها. تم استخراج جيلاتين السمك من جلد أسماك البلطي، حيث تم استخدام طريقة التذويب ذي الخطوتين لإنتاج الجزيئات النانوية الجيلاتينية السمكية. تم تحسين خطوة التذويب الأولى للحصول على وزن جزيئي مرتفع وثابت. وجد أنه بالإمكان إنتاج جيلاتين ثابت ذو وزن جزيئي مرتفع على تركيز 9%، ودرجة حرارة 45 درجة مئوية، وطرد مركزي بسرعة 12000 دورة في الدقيقة ولمدة 5 دقائق. وبهذا تم تطوير طريقة جديدة لإنتاج جزيئات نانوية جيلاتينية سمكية بتجانس عال بناء على خطوة التحسين الأولى. للمزيد من التحسين تم أيضاً تحسين خطوة التذويب الثانية لطريقة التذويب ذي الخطوتين. تم مسح العوامل المهمة باستخدام تصميم بلاكيت-بورمان، وقد تم اكتشاف أن العوامل الهامة كانت الحموضة ونسبة الأستون وحجم الجلوتارالدهيد. ثم تم تحسين العوامل المهمة باستخدام التصميم العامل. وجد أن الجزيئات النانوية الجيلاتينية السمكية بحجم  $6.1 \pm 198.46$  نانومتر تم إنتاجها على حموضة 2.45 وتركيز أستون 16% وحجم الجلوتارالدهيد على 400 ميكرو لتر. أدت زيادة الحموضة وتركيز الأستون إلى زيادة حجم الجزيئات، بينما أدت زيادة حجم الجلوتارالدهيد إلى تقليل حجم الجزيئات. قدم هذا العمل عملية الإنتاج المحسنة، مما يوفر الإمكانيات الواضحة للتطبيقات المستقبلية للجزيئات النانوية الجيلاتينية السمكية. تم الكشف أيضاً أن جيلاتين السمك بإمكانه أن يكون بديلاً لجيلاتين الثدييات لإنتاج الجزيئات النانوية، كما تم تحسين عملية إنتاج الجزيئات النانوية الجيلاتينية السمكية المحملة بالأدوية. تم مسح العوامل الهامة لكفاءة التغليف باستخدام التصميم العامل، وقد وجد أن كمية الدواء فقط لها تأثير كبير في حين أن معدل الحموضة وتركيز الأستون وكمية الجلوتارالدهيد ووقت التحريك لم تكن ذات أهمية لكفاءة الأدوية المغلفة بالجزيئات النانوية الجيلاتينية السمكية. زيادة كمية الدواء زادت أيضاً تغليف الجزيئات النانوية الجيلاتينية السمكية المحملة بالأدوية. تم ملاحظة أن كفاءة التغليف كانت بنسبة 39%. للجزيئات النانوية الجيلاتينية السمكية المحملة بالأدوية. تمت دراسة التوصيف الفيزيائي والكيميائي للصيغة المقترحة المثلى. أظهر مجهر المسح الإلكتروني، والمجهر الإلكتروني النافذ، ومجهر القوة الذرية أن سطح الجزيئات النانوية الجيلاتينية السمكية كان أملساً. كشف تحليل مطياف فورييه عن

وجود عقار في الجزيئات النانوية الجيلاتينية السمكية المصممة. أظهر تحليل حيود الأشعة السينية بالمسحوق تشكل أنظمة مشتتة بشكل غير متبلور. تمت ملاحظة سلوك إطلاق أسرع بقليل في الجزيئات النانوية الجيلاتينية السمكية المحملة بالأدوية مع سلوك إطلاق ثنائي الطور. اتبعت آلية الإطلاق الانتشار غير الفيكاني، مما يعني أن إطلاق الدواء من الجزيئات النانوية الجيلاتينية السمكية كان محكومًا بانتشار وتآكل المصفوفة.



## **APPROVAL PAGE**

The thesis of Deni Subara has been approved by the following:

---

**Irwandi Jaswir**  
Supervisor

---

**Ibrahim Ali Noor Batcha**  
Co-Supervisor

---

**Ma'an Fahmi Rashid Al-khatib**  
Co-Supervisor

---

**Ahmad Jalal Khan Chowdhury**  
Internal Examiner

---

**Norilhan Abdullah**  
External Examiner

---

**Hadi Nur**  
External Examiner

---


**Imad Fakhri Alshaikjli**  
Chairman

## DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Deni Subara

Signature ..... Date .....



**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**OPTIMIZATION OF THE PROCESS EXTRACTION AND DRUG  
RELEASE OF FISH GELATIN NANOPARTICLES DERIVED  
FROM TILAPIA (*Oreochromis Spp*)**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2021 Deni Subara and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Deni Subara

.....  
Signature

.....  
Date

## ACKNOWLEDGEMENTS

*In the Name of Allah, the Gracious, the Merciful*

All praise and thanks be to Allah, the lord of the worlds. May the peace and blessings of Allah be upon Prophet Muhammad, his family and his companions. Thank to Almighty Allah for giving me strength and the ability to complete this research work.

My sincere appreciations goes to my first teachers, guidance and sponsor my dear parents, Mr Syamsuner and Mrs Yurniati for their endless love and encouragement throughout my study. Without your parental guidance since my birth, I won't have gotten this far. I also owe my beloved sister, whose giving never cease and to whom my love increase day by day.

I would like to owe a debt of gratitude to my supervisor Prof. Dr. Irwandi Jaswir, for constantly challenging me intellectually, for his guidance and for believing in me throughout this research process. I appreciate all his contributions of time, support, and ideas. My appreciation also goes to my co-supervisor, Prof. Dr. Ibrahim Ali Noorbacha for his kind support and meaningful contributions, Assoc. Prof. Dr. Ma'an Fahmi Rashid Al-Khatib for kindness and encouragement throughout the study.

I also express special gratefulness to my wife, Mrs Putri Yunita, and my little angel Faradila Deyura. They have provided me with moral supports needed for the completion of this programme.

Finally, I like to thank to all NANORG research unit members as well as the Department of Biotechnology Engineering for providing the facilities to conduct this study. I would also like to express my gratitude to our technical staff that directly and indirectly helped me in accomplishing this study. I am indebted to my colleagues in the Department of Biotechnology Engineering for their moral supports during the course of my programme.

# TABLE OF CONTENTS

Abstract .....	ii
Abstract in Arabic .....	iv
Approval Page .....	vi
Declaration .....	vii
Copyright .....	viii
Acknowledgements .....	ix
List of Tables .....	xiv
List of Figures .....	xv
List of Abbreviations .....	xviii
List of Symbols .....	xx
<b>CHAPTER ONE: INTRODUCTION .....</b>	<b>1</b>
1.1 Research Background .....	1
1.2 Problem Statement and Significance of Study .....	3
1.3 Research Philosophy .....	5
1.4 Research Objectives .....	6
1.5 Research Methodology .....	6
1.6 Scope of Study .....	8
1.7 Thesis Organization .....	9
<b>CHAPTER TWO: LITERATURE REVIEW .....</b>	<b>10</b>
2.1 Introduction .....	10
2.2 Nanoparticles for Drug Delivery System .....	10
2.3 Material for Nanoparticle Preparation .....	11
2.4 Protein for Base Material of Nanoparticles .....	13
2.5 Mammalian Gelatin and Fish Gelatin .....	14
2.6 Fabrication Technique for Production of Gelatin Nanoparticles .....	20
2.6.1 Nanoprecipitation .....	21
2.6.2 Simple w/o Emulsion .....	22
2.6.3 Coacervation .....	23
2.6.4 Desolvation .....	24
2.6.5 Two-step Desolvation .....	24
2.7 Effects of Production Parameters on Gelatin Nanoparticles .....	26
2.7.1 Effect of Mean Molecular Weight of Gelatin on First-Step Desolvation .....	27
2.7.2 Effect of pH During Desolvation .....	29
2.7.3 Effect of Volume of Desolvating Agent .....	30
2.7.4 Effect of Volume of Cross-Linking Agent .....	31
2.7.5 Effect of Stirring Time and Stirring Speed .....	33
2.8 Drug Loading Into Gelatin Nanoparticles .....	36
2.9 Drug Release From Gelatin Nanoparticle .....	40
2.10 Design of Methodology .....	41
2.11 Chapter Summary .....	42

<b>CHAPTER THREE: MATERIALS AND METHOD.....</b>	<b>44</b>
3.1 Introduction .....	44
3.2 Materials .....	44
3.3 Methods .....	45
3.3.1 Fish Gelatin Preparation.....	45
3.3.2 Fish Gelatin Nanoparticles Preparation .....	45
3.3.2.1 Fabrication of Fish Gelatin Nanoparticles by Conventional Two-step Desolvation Method .....	45
3.3.2.2 Fabrication of Fish Gelatin Nanoparticles by Modified Fractionation Step.....	46
3.3.2.3 Fabrication of Drug-Loaded Fish Gelatin Nanoparticles by Modified Two-step Desolvation Method.....	47
3.3.3 Experimental Design.....	48
3.3.3.1 Experimental Design for Screening of Factors Influencing Mean Molecular Weight (first desolvation step).....	48
3.3.3.2 Experimental Design for Screening the Significant Factor for Production of Fish Gelatin Nanoparticles.....	48
3.3.3.3 Experimental Design for Selecting the Range of Level from Significant Factor for Production of Fish Gelatin Nanoparticle.....	50
3.3.3.4 Experimental Design for Optimization of Production Factors of Fish Gelatin Nanoparticles Using Face Centred Central Composite Design (FCCCD).....	51
3.3.3.5 Experimental Design for Screening of Production Factors of Drug-Loaded Fish Gelatin Nanoparticles Using Fractional Factorial Design (FFD) .....	54
3.3.4 Analytical Analysis .....	54
3.3.4.1 Determination of HMW Content Using SDS-PAGE .....	54
3.3.4.2 Determination of Drug Loading .....	55
3.3.4.3 Determination of Drug Release .....	55
3.3.5 Characterization of Fish Gelatin Nanoparticles and Salicylic Acid Loaded Fish Gelatin Nanoparticles.....	56
3.3.5.1 Particles Size and Particle Distribution using Zeta Sizer .	56
3.3.5.2 Particles Charge Using Zeta Potential .....	56
3.3.5.3 Fungsional Group Analysis Using Fourier Transform Infrared spectroscopy.....	56
3.3.5.4 Thermal Characterization using Differential Scanning Calorimeter (DSC).....	57
3.3.5.5 Surface Characterization Using Atomic Force Microscopy (AFM) .....	57
3.3.5.6 Morphology Characterization using Scanning Electron Microscopy (SEM) .....	57
3.3.5.7 Morphologies Characterization using Transmission Electron Microscopy (TEM).....	58
3.3.5.8 Thermal Gravimetric Analysis (TGA) .....	58
3.3.5.9 X-ray Diffraction Analysis .....	58

<b>CHAPTER FOUR: RESULTS AND DISCUSSION .....</b>	<b>59</b>
4.1 Introduction .....	59
4.2 Increasing of Mean High Molecular Weight Gelatin Content of Precipitate in Fractionation Step .....	59
4.2.1 Effects of Several Precipitation Factors on High Molecular Weigh Content .....	61
4.2.1.1 Effects of Gelatin Concentration on Mean Molecular Weight of Precipitate .....	61
4.2.1.2 Effects of Temperature on Mean Molecular Weight of Precipitate .....	62
4.2.1.3 Effects of Centrifugation Speed on Mean Molecular Weight of Precipitate .....	64
4.2.1.4 Effects of Centrifugation Time on Mean Molecular Weight of Precipitate .....	65
4.2.2 Validation .....	66
4.3 Screening and Optimization of Second Desolvation Step for Production of Fish Gelatin Nanoparticles .....	69
4.3.1 Screening of Factors Influencing Production of Fish Gelatin Nanoparticles Using Plackett-Burman Design .....	70
4.3.2 Effects of Several Production Factors on Fish Gelatin Nanoparticles Size .....	75
4.3.2.1 Effect of pH .....	75
4.3.2.2 Effect of Acetone Concentration .....	78
4.3.2.3 Effect of Glutaraldehyde Amount as Crosslinking Agent .....	80
4.3.2.4 Effect of Stirring Speed .....	81
4.3.2.5 Effect of Stirring Time .....	82
4.3.3 Optimization by Response Surface Methodology .....	83
4.3.4 Validation of Model .....	89
4.4 Production of Drug Loaded Fish Gelatin Nanoparticles .....	91
4.4.1 Screening of Significant Factors for Production of Salicylic Acid-Loaded Fish Gelatin Nanoparticles Using Fractional Factorial Design .....	91
4.4.2 Effect of Factors Influencing Drug-Loaded Fish Gelatin Nanoparticle .....	96
4.4.2.1 Effect of pH .....	96
4.4.2.2 Effect of Drug Amount .....	98
4.4.2.3 Effects of Acetone Concentration .....	99
4.4.2.4 Effects of Glutaraldehyde .....	101
4.4.2.5 Effects of Stirring Time .....	102
4.4.3 Optimization by One-Factor-At-Time and Validation of Model .....	103
4.5 Characterization of Fish Gelatin Nanoparticles And Drug-Loaded Fish Gelatin Nanoparticles .....	105
4.5.1 Size and Zeta Potential .....	105
4.5.2 Drug Release from Fish Gelatin Nanoparticles .....	106
4.5.3 Scanning Electron Microscopy (SEM) .....	108
4.5.4 Transmission Electron Microscopy (TEM) .....	109
4.5.5 Atomic Force Microscopy (AFM) .....	111
4.5.6 Fourier-Transform Infrared (FTIR) .....	112

4.5.7 X-ray Diffraction (XRD) .....	114
4.5.8 Differential Scanning Calorimetry (DSC) .....	116
4.5.9 Thermo-Gravimetric Analysis (TGA) .....	117
<b>CHAPTER FIVE: CONCLUSION AND RECOMMENDATIONS .....</b>	<b>119</b>
5.1 Conclusion .....	119
5.2 Major Findings .....	121
5.3 Recommendations.....	122
<b>REFERENCES.....</b>	<b>124</b>
<b>CONTRIBUTION OF THE STUDY .....</b>	<b>140</b>
Appendix A.....	143



## LIST OF TABLES

Table 2.1	Amino acid composition of fish and mammalian gelatin	18
Table 2.2	Applications of Fish Skin Gelatin	19
Table 2.3	Advantages and disadvantages of different production methods for gelatin nanoparticles	25
Table 2.4	Drug loaded and Method for production GNPs	34
Table 3.1	Factors and levels for screening significant factors, total volume of the mixture is kept at 100 mL	49
Table 3.2	Experimental design of Plackett-Burman for screening the significant factors	50
Table 3.3	Independent variables and their corresponding levels of second desolvation step	52
Table 3.4	Experimental Layout RSM	53
Table 4.1	Experimental design and results of the face center central composite design	71
Table 4.2	ANOVA for the parameters of RSM	71
Table 4.3	Experimental design and results of the face central composite design	84
Table 4.4	Analysis of variance (ANOVA) for the parameters of response surface methodology fitted to second-order polynomial equation	86
Table 4.5	FGNPs size on the formulated processes	91
Table 4.6	Experimental design and results of the factorial design	92
Table 4.7	Analysis of variance (ANOVA) for the parameters of response surface methodology fitted to second-order polynomial equation	95
Table 4.8	Fitting of Release Kinetic Model to SA Release Data for FGNP (Size 196 nm)	108
Table 4.9	Band of amides A, B, I, II, and III for the samples, according to the FTIR spectra	113

## LIST OF FIGURES

Figure 2.1	Basic chemical structure of Gelatin	15
Figure 4.1	SDS-PAGE gel electrophoresis result of fish gelatin precipitated by difference in the concentration of gelatin (a) marker, (b) fish gelatin solution 3%,(c) 5%, (d) 7%, (e) 9%, (f) 13%, (g) 18%, (h) 23%, and (i) 30% (g/v) respectively. Each experiment was performed in triplicate.	62
Figure 4.3	SDS-PAGE gel electrophoresis result of fish gelatin precipitated by difference in the centrifugation speed;(a) marker, (b) speed 6000 x g,(c) speed 9000 x g, (d) speed 12000 x g, (e) speed 15000 x g, (f) 18000 x g,	65
Figure 4.4	SDS-PAGE gel electrophoresis result of fish gelatin precipitated by difference in the centrifugation time ;(a) marker, (b) 1 min,(c) 3 min, (d) 5 min, (e) 7 min, and (f) 15 min respectively. Each experiment was performed in triplicate.	66
Figure 4.5	Figure A is the SDS-PAGE results of fish gelatin precipitate a and b is marker, c) fish gelatin precipitate prepared with centrifugation, d) fish gelatin precipitate without centrifugation, Figure B is size distribution of fish gelatin nanoparticles, a) fish gelatin nanoparticles produced by centrifuge method, b) fish gelatin nanoparticles produced by the conventional method.	68
Figure 4.6	The differences of SEM images between conventional precipitation and modified precipitation step	69
Figure 4.7	Pareto chart of RSM	73
Figure 4.8	Effect of production factor for preparing FG	74
Figure 4.9	Effect of different pH levels to nanoparticles size, while Acetone concentrations at 40% (vol%), glutaraldehyde volume at 350 µl, stirring speed at 600 rpm and stirring time at 6 h. Significant differences by student's t-test are marked by asterisk, P<0.05.	76
Figure 4.10	UV-Vis absorption (at 360 nm) of fish gelatin aqueous (1% w/v) at different pH	77
Figure 4.11	Effect of different acetone concentration levels to nanoparticles size, while pH at 3.5, glutaraldehyde volume at 350 µl, stirring	

speed at 600 rpm and stirring time at 6 h. Significant differences by student's t-test are marked by asterisk, $P < 0.05$	78
Figure 4.13 Effect of different stirring speed levels to nanoparticles size, while pH at 3.5, acetone concentration 40% (vol%), glutaraldehyde volume at 350 $\mu$ l, and stirring time at 6 h	81
Figure 4.14 Effect of different stirring time levels to nanoparticles size, while pH at 3.5, acetone concentration 40% (vol%), glutaraldehyde volume at 350 $\mu$ l, and stirring speed at 600 rpm	82
Figure 4.15 Three dimension response surface plots of the effect of independent variables on particle sizes of FGNP showing interaction between acetone concentrations vs pH (A); glutaraldehyde volume vs pH (B); glutaraldehyde volume vs acetone percentage (C)	89
Figure 4.16 Pareto chart of factorial design	93
Figure 4.17 Predicted versus actual value of experiment factorial design	95
Figure 4.18 Effect of pH to encapsulation efficiency	98
Figure 4.20 Effect of acetone concentration to encapsulation efficiency	100
Figure 4.21 Effect of glutaraldehyde volume to encapsulation efficiency	102
Figure 4.23 Effect of drug concentration on encapsulation efficiency, while gelatin mass at 0.9 g, pH at 2.5, Acetone concentration at 16%, glutaraldehyde volume at 400 $\mu$ l, and stirring time at 6 h.	105
Figure 4.25 SEM images of fish gelatin nanoparticle (a), and drug-loaded fish gelatin nanoparticles (b)	109
Figure 4.26 TEM images of FG NPs (a), and drug-loaded FG NPs (b)	110
Figure 4.27 AFM image of two dimension of FG NPs (a), three dimensions of FG NPs (b), two dimensions of drug-loaded FG NPs (c), and three dimension of drug-loaded FG NPs (d).	111
Figure 4.28 FTIR spectra of fish gelatin (a), fish gelatin nanoparticles (b) in the optimum formulation, drug-loaded FG NPs (c), and pure drug (d).	112
Figure 4.29 XRD spectrum of FG NPs, drug loaded FG NPs and pure drug	115

Figure 4.30. DSC thermograms of fish gelatin (a), and fish gelatin nanoparticles (b) in the optimum formulation 117

Figure 4.31 TGA curve of FG NPs, drug-loaded FG NPs and pure drug 118



## LIST OF ABBREVIATIONS

A	absorbance
ALP	Alkaline Phosphatase
ANOVA	Analysis of Variance
AFM	Atomic Force Microscopy
BSE	Bovine Spongiform Encephalopathy
BSA	Bovine Serum Albumin
°C	degree(s) Celcius
DNA	Deoxyribonucleic Acid
DSC	Differential Scanning Calorimeter
DL	Drug Loading
<i>dW</i>	distilled water
EE	Encapsulation Efficiency
FDA	Food and Drug Agency
FE-SEM	Field Emission Scanning Electron Microscope
FGNPs	Fish Gelatin Nanoparticles
FTIR	Fourier Transform Infra-Red
Fig	Figure
GA	Glutaraldehyde
GPNs	Gelatin Nanoparticles
GRAS	Generally Regarded As Safe
HMW	High Molecular Weigh
HPLC	High Performance Liquid Chromatography
IUM	International Islamic University Malaysia
IR	Infra-Red
kDa	kilo Dalton
$K_p$	release constant
LMW	Low Molecular Weigh
M	Molar
MW	Molecular Weight
NPs	Nanoparticles
PBS	Phosphate Buffer Saline
PCS	Photon Correlation Spectroscopy
PdI	Poly dispersity Index
RSM	Response Surface Methodology
RT	Retention Time
SA	Salicylic Acid
SD	Standard Deviation
SEM	Scanning Electron Microscope
<i>t</i>	time
T	Temperature
TEM	Transmission Electron Microscopy
TGA	Thermal Gravimetric Analysis
USA	United States of America
UV	Ultraviolet
W	Weight


W/O  
XRD

Water-in-oil  
X-ray Diffraction



## LIST OF SYMBOLS

%	percentage
µg	microgram
µl	microliter
µmol	micromole
µg/ml	microgram per milliliter
M	molarity
g	gram
g/g	gram per gram
g/l	gram per liter
h	hour
l	liter
ml	milliliter
°C	Degree Celsius (temperature)
v/v	volume per volume
w/v	weight per volume
rpm	rotations per minute



# CHAPTER ONE

## INTRODUCTION

### 1.1 RESEARCH BACKGROUND

The use of fishery waste such as fish skin as the source of gelatin has been associated with many advantages. In particular, one of its potentials lies in the properties of biodegradability and low toxicity, thus representing itself as a good raw material (Elgadir et al., 2013; Ismail & Abdullah, 2016). More importantly, its sourcing and collection from fishery wastes are easy; for example, Malaysia's frozen tilapia fillet exports to the European Union were increased by 13% in 2014, followed by Indonesia and Vietnam (Fish, 2015).

Gelatin is a polymer material produced from hydrolyzed collagen, which is extracted mostly from bovine bone, pigskin, and fish skin. Previous studies have thus far been limited towards the use of mammalian gelatin for the production of gelatin nanoparticles and drug encapsulation. For examples, bovine gelatin has been incorporated to encapsulate metformin in treating bone defects (Shahrezaee et al., 2018), while studies on porcine gelatin have been conducted for anti-microbial (Kirar, Thakur et al., 2018) and anti-tubercular licorice extract encapsulation (Viswanathan et al., 2018). However, no report has been released till date regarding the production of gelatin nanoparticles made of fish gelatin.

It should be noted that the usage of materials of mammalian origin in drugs and food products is limited due to religious and ethical reasons. Beyond the forbidden consumption of porcine gelatin among Jewish and Muslim groups (Sadowska et al., 2003), the emergence of Bovine Spongiform Encephalopathy (BSE)

in Europe decade ago has raised several questions concerning the use of pig gelatin for relevant applications (Pang et al., 2017). Under such circumstances, materials of fish origin serve as an alternative for producing gelatin nanoparticles. Furthermore, fish-based gelatin is rarely employed to produce gelatin nanoparticles, wherein it is geared for the production of gelatin film (Hosseini et al., 2016), and nanofibre (Kwak et al., 2017) till date. As such, it is advisable to carry out experimentation for the purpose of gelatin nanoparticles manufacturing from fish gelatin and further optimize the production process.

In general, several methods have been employed for gelatin nanoparticle production, such as emulsion (E. J. Lee & Lim, 2017), coarcevation (Patra et al., 2016), self-assembly (Z. Li & Gu, 2011), and desolvation (Carvalho et al., 2018). Among these approaches, the desolvation method has been found to offer small particle sizes and narrow size distribution (Sahoo et al., 2015). The production of this material is typically dependent on the factors chosen, wherein their selection is guided by the gelatin characteristics itself, which are also dictated by the resources (Ingvild J. Haug et al., 2004). Therefore, one can expect differences between gelatin made from mammalian and fish sources accordingly. For example, gelatin is specifically characterized by its triple helical structure. Moreover, its proline and hydroxyproline contents differ accordingly; mammalian sources account for 30%, while warm-water fishes such as tilapia and Nile perch log 22-25% (Muyonga et al., 2004). As a result of these differences, fish-based gelatin generates a lower gel modulus and melting temperature in comparison with its mammalian counterpart. Thus, the conditions required for fish gelatin nanoparticle production may vary to that of mammalian gelatin nanoparticle.

Accordingly, the current research aims to investigate the use of fish gelatin extracted from local fish waste (i.e. fish skin) as the main source for nanoparticle production. To this end, the two-step desolvation method is adopted and the optimized factor is selected accordingly. The process includes a look into drug encapsulation using fish gelatin nanoparticles, following which statistical methods are employed to determine the optimum processing conditions for both fish gelatin nanoparticles and drug-loaded fish gelatin nanoparticles. Then, the characteristics of both nanoparticle types are analyzed.

## **1.2 PROBLEM STATEMENT AND SIGNIFICANCE OF STUDY**

In general, the currently employed raw materials for gelatin production are primarily sourced from mammalian skins and bones, which are either bovine or porcine in nature. According to different ethical, religious, and health reasons, the use of such gelatin in various food and non-food products are some of the main issues highlighted by Muslims, Jews, vegetarians, and people of other religious backgrounds. Hence, the demand for fish gelatin is now on the increase, which is further supplemented by aquaculture being identified as a means for increasing fish production in Malaysia and the huge resources invested for tilapia production. In this regard, fish skin is a major and expansive by-product of the domestic fish-processing industry that has systemically caused wastage and pollution, which may thus provide the sought-after source of gelatin. Furthermore, fish gelatin offers the advantages of cheap cost and easy availability. However, no report has been presented regarding the production of gelatin nanoparticles made from tilapia fish skin thus far. Hence, this effort is highly significant due to the sustainable raw material that is readily accessible and towards fortifying the Halal industry in Malaysia.

The two-step desolvation method offers a straightforward process and produces nanoparticles of the desired size (Geh et al., 2016; S.A. Khan & Schneider, 2013). Therefore, it is chosen for the production of fish gelatin nanoparticles in this study, wherein the first step of desolvation allows the removal of low molecular weight gelatin. This will allow the remaining high molecular weight gelatin to form dense and small-sized particles after cross-linking occurs (Azarmi et al., 2006; Sahoo et al., 2015). However, the experimental session is done in batch to batch dependent on each other, which will result in high molecular weight content heterogeneities after cleaving off the low molecular weight given the gelatin's tendency nanoparticles to form un-uniformly. Collectively, these findings indicate that designing improved methods for a consistently high molecular weight gelatin obtainment is sorely needed.

Furthermore, fish and mammalian gelatin both typically have the same characteristics. However, the content of imino acid in fish gelatin is less compared to mammalian gelatin, which results in its lower gelling and melting temperatures (Ingvild J. Haug et al., 2004; Muyonga et al., 2004). Moreover, previous works of relation have only focused on optimizing the process production for the second step of the two-step desolvation method in mammalian gelatin nanoparticle manufacturing. Hence, this reflects the present need for research efforts emphasizing an optimized process of fish gelatin nanoparticle production.

Besides, it is known that a successful nanoparticle system should possess a high loading capacity to reduce the amount of carrier required for administrative purposes. The benefits of fish gelatin usage for gelatin nanoparticle production by using an optimized process is undeniable. The material is associated with perks such as reduced waste from frozen fillet production, increased economic value of waste